Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms IBS-3001
  • Sponsors Furiex Pharmaceuticals

    • Most Recent Events

    • 13 Oct 2020 Results of aggregated pooled analysis from two phase III studies: NCT01553591 and NCT01553747 and one phase IV study: RELIEF presented at the 28th United European Gastroenterology Week
    • 19 May 2020 Results of an analysis assessing range of abdominal and bowel symptoms in patients with irritable bowel syndrome with diarrhea reporting inadequate symptom control with Loperamide from two Phase 3 trials (NCT01553591 and NCT01553747) and one phase IV trial (RELIEF: NCT02959983), were published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
    • 01 Nov 2017 Results of pooled post hoc analysis of IBS-3001 and IBS-3002 trials assessing responder and non-responder rates over 4-week intervals and the proportion of responders/non-responders who continued or discontinued treatment presented at the 25th United European Gastroenterology Week
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top